Welcome to our dedicated page for Spyre Therapeutics SEC filings (Ticker: SYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Spyre Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Spyre Therapeutics's regulatory disclosures and financial reporting.
Spyre Therapeutics, Inc. is proposing a primary offering of $300,000,000 of common stock on the Nasdaq Global Select Market (symbol SYRE), with underwriters holding a 30-day option to purchase additional shares. The prospectus states a last reported sale price of $51.29 per share on April 10, 2026.
The company reported positive 12-week SKYLINE Part A induction topline results for SPY001 (change in RHI: -9.2, p<0.0001), said Part A recruitment is closed and Part B enrollment is open, and expects further readouts mid-2026 and in 2027. Spyre also reported approximately $741 million of cash, cash equivalents and marketable securities as of March 31, 2026 (preliminary).
Spyre Therapeutics, Inc. reported preliminary cash, cash equivalents and marketable securities of approximately $741 million as of March 31, 2026, including $30 million of legacy asset disposition proceeds. About $23 million of these proceeds is expected to be paid to contingent value rights holders in the second quarter of 2026.
These figures are unaudited, subject to closing procedures and may change. Effective April 13, 2026, the company suspended and terminated its at-the-market offering prospectus under its Sales Agreement with TD Securities (USA) LLC, so no further ATM sales will occur unless a new prospectus or registration statement is filed.
Spyre Therapeutics reported positive 12-week induction results from Part A of its Phase 2 SKYLINE trial of SPY001 in moderate-to-severely active ulcerative colitis. SPY001 met the primary endpoint with a statistically significant 9.2-point reduction in Robarts Histopathology Index (p<0.0001).
Key secondary endpoints were also encouraging, with clinical remission by modified Mayo Score in 40% of patients and endoscopic improvement in 51%. Among 43 treated patients, 14% experienced treatment-emergent adverse events and one serious event, which investigators deemed not drug-related, supporting a safety profile consistent with the α4β7 class. Part A recruitment is closed and Part B, including monotherapy and combination cohorts, is now enrolling with additional readouts expected in 2026 and 2027.
Spyre Therapeutics, Inc. is holding its 2026 virtual annual stockholder meeting on May 27, 2026 to vote on four key items. Stockholders will elect three Class I directors, cast an advisory “say-on-pay” vote on executive compensation, ratify KPMG LLP as auditor, and approve an amended and restated 2016 Employee Stock Purchase Plan reserving 1,056,096 shares. The company highlights its classified board, supermajority voting and other governance practices, and notes 78,784,358 common shares outstanding as of April 2, 2026.
Spyre Therapeutics, Inc. Chief Executive Officer Turtle Cameron reported open-market sales of company stock. On April 1, 2026, he sold a total of 15,000 shares of common stock in two transactions, at weighted average prices of $49.20 and $49.92 per share.
The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025. After these transactions, Cameron directly holds 627,540 shares of Spyre Therapeutics common stock, including 116,168 shares that vest in monthly installments through November 2026, contingent on his continued service.
Spyre Therapeutics, Inc. Chief Medical Officer Sloan Sheldon exercised stock options and sold the resulting shares. On this Form 4, Sheldon exercised options to acquire 7,958 shares of common stock at an exercise price of $21.66 per share and immediately sold all 7,958 shares at $50.00 per share.
The filing notes that this transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025, indicating the timing was set in advance rather than being a discretionary market-timing decision.
Spyre Therapeutics Chief Financial Officer Scott L. Burrows reported an option exercise and related stock sales. On April 1, 2026, he exercised stock options to acquire 7,500 shares of common stock at an exercise price of $14.50 per share, fully using the remaining options covered in this filing.
On the same date, he sold 6,200 shares at a weighted average price of $49.21 and 1,300 shares at a weighted average price of $49.98 in open-market transactions, executed under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly held 97,994 shares of common stock, including 67,476 restricted stock units scheduled to vest in equal installments on September 1, 2026 and September 1, 2027, subject to continued employment.
The Vanguard Group filed Amendment No. 1 to a Schedule 13G/A reporting beneficial ownership of 0 shares of Spyre Therapeutics Inc Common Stock. The amendment explains an internal realignment effective January 12, 2026 that led certain Vanguard subsidiaries to report holdings separately; the filing states the reported holdings include securities in the form of rights.